A Potentially Fatal New COVID-Related Syndrome Has Emerged

Even mild infections may be sufficient to trigger this serious condition.

In the northern regions of England, a concerning trend is unfolding—a surge in cases of a rare yet deadly autoimmune disorder known as Anti-MDA5 positive dermatomyositis. What makes this outbreak particularly alarming is its apparent connection to COVID-19, suggesting that even mild infections may be sufficient to trigger this serious condition.

Historically prevalent primarily among Asian populations, Anti-MDA5 positive dermatomyositis is now disproportionately affecting the Caucasian residents of Yorkshire. This autoimmune disorder targets an enzyme called MDA5, resulting in progressive interstitial lung disease marked by the scarring of lung tissue. Shockingly, between 2020 and 2022, doctors in Yorkshire reported an unprecedented 60 cases of MDA5 autoimmunity, leading to eight tragic deaths.

A recent study shedding light on this surge suggests a correlation between the rise in cases and the major waves of COVID-19 infections during the peak years of the pandemic. MDA5, a crucial RNA receptor involved in recognizing the SARS-CoV-2 virus, has piqued researchers’ interest as a potential link to this autoimmune response.

The study authors highlight the emergence of a distinct form of MDA5+ disease in the COVID-19 era, labeled “MDA5-autoimmunity and Interstitial Pneumonitis Contemporaneous with COVID-19” (MIP-C). Utilizing advanced data-crunching tools, researchers uncovered a shared trait among patients with MDA5 autoimmunity—elevated levels of interleukin-15 (IL-15), an inflammatory cytokine.

Dr. Pradipta Ghosh, one of the study authors, elucidated on this discovery, explaining how IL-15 can drive cells towards exhaustion, a hallmark of progressive interstitial lung disease. Strikingly, only eight of the 60 patients had previously tested positive for COVID-19, suggesting that asymptomatic infections may also serve as triggers for MDA5 autoimmunity.

The timing of the surge in MDA5 positivity testing, coinciding with the peaks of COVID-19 cases and vaccinations in 2021, suggests a potential immune reaction or autoimmunity against MDA5 following exposure to the virus or vaccine. Moreover, reports of MIP-C are now emerging from various parts of the globe, indicating that this phenomenon extends beyond Yorkshire.

As the medical community grapples with understanding and addressing MIP-C, these findings underscore the complexities of the immune response to COVID-19 and the need for continued vigilance in monitoring and managing potential complications. Efforts to unravel the mechanisms underlying this newly-identified syndrome are crucial in safeguarding public health amidst the ongoing pandemic.